Aumbio
Wellness & Personal Care · Medical Clinics
- Active units
- 0
- Royalty
- 6.0%
Franchised, year-end 2024
of weekly Net Sales
About Aumbio
AUM Biosciences is a leading bio-pharmaceutical company specializing in the development and commercialization of innovative cancer therapies. With a team of industry veterans at the helm, including Vishal Doshi as Chairman and Chief Executive Officer, AUM Biosciences is committed to driving advancements in cancer treatment. Their focus lies in developing cutting-edge therapies that target various types of cancer, and they have a strong pipeline of potential breakthrough drugs. AUM Biosciences' pipeline includes AUM001, AUM601, AUM302, and AUM003, all of which hold great promise in improving patient outcomes. Backed by a distinguished group of scientific advisors, AUM Biosciences ensures that their research and development efforts are guided by top experts in the field. With offices in Singapore, the USA, Australia, and China, they are able to collaborate globally and expand their reach. Investors appreciate AUM Biosciences' commitment to excellence, evident in their robust clinical trials, publications, and posters. They also offer a comprehensive investor kit and keep stakeholders updated through press releases, news, and events. AUM Biosciences is dedicated to making a significant impact in the fight against cancer, and their unwavering dedication is evident in everything they do. Get in touch with them to learn more about their groundbreaking advancements in cancer therapies.
Key terms
- Franchise fee
$50k
- Multi-unit / early adopter discretion
We may discount the Initial Franchise Fee for Franchisees that purchase multiple franchises or multiple territories or to early adopters.
- Brand fund
1.0% of Net Sales
- Local advertising
1500.0% of Net Sales
- Footprint
700 – 1,500 sq ft
- Multi-Unit Development Agreement
$50k
- Multi-Unit Development Agreement
$90k
- Multi-Unit Development Agreement
$125k
- Veteran discount
Not offered
Brand Percentile Rankings
Rankings compare brands in the same operating year. Fee and investment figures come from the FDD (2026 filing); filings on file: 2025, 2026.
Growth
- Total locations0
Franchised units open at year-end
- New openings0
Gross new units opened during the calendar year
- 1-year unit growth rate—
Net unit growth versus prior year
- 3-year unit CAGR—
Compound annual growth rate of unit count over the trailing 3 years
- Unit growth ratio0.0×
Cumulative opens / closures through year-end
Unit economics
- Annual unit volume (Median)—
Per FDD Item 19 disclosure
- Annual unit volume (25th percentile)—
Per FDD Item 19 disclosure
- Annual unit volume (75th percentile)—
Per FDD Item 19 disclosure
- 1-year Median AUV growth rate—
Year-over-year change in median AUV
- Store-level EBITDA Margin—
Median unit-level EBITDA / AUV
Investment profile
- Estimated initial investment—
Midpoint of estimated initial investment range
- Time to open—
Midpoint of average time from agreement to opening
- Royalty rate6.0%
Percent of net sales paid to the franchisor
↓ Lower is better - Sales-to-investment ratio—
Median AUV / estimated initial investment midpoint
- Cash-on-cash returns—
Median unit-level EBITDA / estimated initial investment midpoint. Steady-state estimate; year 1 returns will be lower as the unit ramps to median volumes.
Franchisee healthLocked
- Unit closure ratio
- Transfer vs. closure ratio
- Percent multi-unit franchisees
- Litigation rate
- EBITDA multiple on sales & transfers
Create your free Glidepath account to access full brand information.
Sources
Financial and operating figures are sourced from the brand's Franchise Disclosure Documents. Brand percentile rankings are based on comparisons to other brands that include the same metrics in their Franchise Disclosure Documents.